Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc)(Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc))

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

Measles mumps and rubella virus vaccine、Measles, Mumps and Rubella Vaccine, Live、Measles, Mumps and Rubella Virus Vaccine Live

+ [4]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline LLCGlaxoSmithKline GmbH & Co. KG

非在研机构

GSK Plc

最高研发阶段批准上市

首次获批日期

德国 (1998-05-31)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

24

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床试验

TCTR20231108008 / Not yet recruiting临床4期

A Phase IV, Non-Inferiority, Double Blind, Randomized Controlled Clinical Trial comparing Safety and Immunogenicity of SII-Measles-Mumps-Rubella vaccine with Priorix (GSK) in healthy infants

开始日期2024-01-01

申办/合作机构-

CTIS2023-503845-79-01 / Not yet recruitingIIT

The induction of respiratory immune responses by epicutaneous vaccinationwith the MMR vaccine - LGS.MMR.02.2022.2025

开始日期2023-06-20

申办/合作机构

Rigshospitalet

NCT05630846 / Active, not recruiting临床2期

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

开始日期2022-12-14

申办/合作机构

GSK Plc

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

2,302

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2025-01-01·VACCINE

Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care

Article

作者: Robson, John ; Wu, Jianhua ; Billington, Anna ; Gutierrez, Ana ; Ahmed, Zaheer ; Marszalek, Milena ; Bedford, Helen ; Smith, Kelvin ; Firman, Nicola ; Hawking, Meredith K.D. ; Dostal, Isabel ; Dezateux, Carol ; Hawking, Meredith K D

BACKGROUND:

We conducted a mixed methods evaluation to assess whether implementing a primary care quality improvement (QI) programme utilising a digital call-and-recall tool improved timely receipt and equity of first measles, mumps and rubella (MMR) and diphtheria tetanus, pertussis and polio-containing (DTaP /IPV) vaccinations.

METHODS:

138,133 and 136,952 children were eligible to receive first MMR and DTaP/IPV respectively between 1st January 2019 and 31st January 2024 in North East London. We compared proportions with timely first MMR or DTaP/IPV receipt (by ages 18 and six months respectively) pre- and post-implementation using an interrupted time series analysis. We calculated change in the Slope Index of Inequality (SII) by an area-level deprivation measure. We conducted 'Think Aloud' exercises and semi-structured interviews with users.

FINDINGS:

The proportion of children with timely first MMR receipt increased by 5·3 % (Rate Ratio [RR]:1·053, 95 % confidence interval [CI]:1·033-1·073), equating to an absolute increase in timely MMR receipt of 4·1 % - from 77·7 % to 81·8 % - and for first DTaP/IPV by 0·9 % (RR:1·009, 95 % CI:1·003-1·015). There was no significant change in SII for either vaccine. Users reported improved recall with tool use, but identified practice-level and systemic barriers, including staff dynamics and unachievable national targets, limiting its consistent use.

INTERPRETATION:

In a real-world setting, a call-and-recall tool within a primary care QI programme improved timely first MMR receipt. Sustained improvement requires additional support including by incentivising achievable targets and improving staff capacity and training.

FUNDING:

National Institute of Health and Care Research; Barts Charity.

2024-12-31·Human vaccines & immunotherapeutics

A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine

Review

作者: Mahajan, Manish ; Shah, Nitin ; Kumar, Kishore ; Ghosh, Apurba ; Dutta, Trayambak

Measles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable responses for anti-mumps antibodies. Most common strains for MMR vaccines, currently available in India, are the Edmonston-Zagreb measles strain, Leningrad Zagreb (L-Z) mumps strain, and the RA 27/3 rubella strain. L-Z strain of mumps virus has been found to be associated with aseptic meningitis by different studies from different parts of the world including India. Recently, a novel freeze-dried MMR vaccine developed by Zydus Lifesciences (Zyvac MMR) contains Edmonston Zagreb measles strain, Hoshino mumps strain, and RA 27/3 rubella strain. The Hoshino strain is WHO approved and was found to induce interferon gamma production. This review article aims to provide a comprehensive appraisal of the data available on the safety and immunogenicity of the novel MMR vaccine.

2024-12-31·Human Vaccines & Immunotherapeutics

Does a correlation exist between delayed vaccination and a decreased vaccine confidence?

Article

作者: Celdrán-Navarro, María Del Carmen ; Reverte, Virginia ; Pérez-Martín, Jaime Jesús ; Zornoza-Moreno, Matilde ; Romera-Guirado, Francisco J. ; Molina-Salas, Yolanda E.

Delay in vaccination schedule may result in increased risk of vaccine-preventable outbreaks. Lack of parental confidence in vaccines and sociodemographic factors could be related to those delays. Vaccine Confidence Index (VCI) is an indicator to estimate confidence in vaccines, composed of simple dimensions about it and evaluated using a 5-point Likert scale. Objectives of this study, conducted in the Region of Murcia, Spain, were to determine which sociodemographic factors were associated with delayed administration in measles, mumps and rubella (MMR) vaccine, both first and second doses, and to evaluate if there were differences in parental vaccine confidence of children who were delayed on MMR vaccine schedule compare to vaccinated on time. The 2019-2020 (first dose) and 2016-2017 (second dose) cohorts were divided into four categories: vaccinated on time, slightly delayed, moderately delayed and highly delayed. Online questionnaire was sent to their parents, followed by a telephone questionnaire for non-responders. Regarding MMR first dose, a significant association was found between delay and birth order and intellectual/motor delay of children. Parental educational status, the main source of vaccine information and the social networks more frequently used by parents were also associated with delay. Suffering motor/intellectual delay and the obstacles to vaccination process derived from caring for other siblings were associated with delay in second MMR dose. The VCI decreased significantly in first dose group as delay increases but did not change in the second one. Confidence in vaccines and sociodemographic factors, respectively, were associated with delaying MMR first and second dose.

15

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的新闻（医药）

2024-12-02

·Endpoints

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Former FDA Commissioner Scott Gottlieb opposed President-elect Donald Trump’s choice to lead the Department of Health and Human Services, saying Robert F. Kennedy Jr.’s policies would lead to a resurgence of preventable diseases and cost lives. Gottlieb led the FDA in the first Trump administration. In comments on CNBC Friday, he called Kennedy (widely known as RFK Jr.) a “committed” anti-vaccine advocate who, if confirmed by the Senate, could easily take steps to decrease the use of vaccines in the US. “I have deep concerns about Kennedy’s stated intentions to roll back core public health protections, particularly as it relates to childhood vaccines,” Gottlieb said. “I think if RFK follows through on his intentions, and I believe he will and I believe he can, it will cost lives in this country.” He said he had raised his objections with Republican senators who will vote on the selection of Kennedy, who Trump announced last month . Trump’s pick of Kennedy has been followed by a series of announcements that would put skeptics of longstanding US healthcare and public health policy in positions of power. Along with Kennedy, that includes Trump’s choice to lead the National Institutes of Health (Stanford researcher and Covid policy skeptic Jay Bhattacharya) and the CDC (former congressman Dave Weldon). While in Congress, Weldon pushed for significant changes to vaccine policy that have been sought by vaccine skeptics. Kennedy has questioned the use of childhood vaccines for years, attempting to link them to the rise of autism and raising other questions about their safety. While his remarks on his exact plans have shifted over time, at their core is the idea that he wants to push away from a policy of vaccine requirements — meant to create widespread immunity and protect those who can’t be vaccinated or who have immune issues — and create a policy of individual choice. “I’m not going to take away anybody’s vaccines,” Kennedy said in a television interview last month. “People can make individual assessments about whether that product is good for them.” The Trump transition team didn’t immediately respond to a request for comment. Gottlieb in particular warned about a resurgence of measles, a highly infectious disease that can be deadly in young children. Vaccination rates of the measles, mumps and rubella (MMR) vaccine have fallen in some parts of the country, and been followed by occasional outbreaks. Nationally, kindergarten vaccination rates are around 92% with two doses of MMR vaccine, according to a CDC study published this year . But in some states, they are far lower. In Idaho, only about 80% of children have received the vaccine. In Wisconsin, the rate is 85%. Those rates are below the 95% target the CDC says is a benchmark for creating population-level immunity to the disease. “If we lose another 5%, we’re going to see a situation where we see distributed outbreaks,” Gottlieb said. “What I worry about is that we’re at a tipping point where we’re going to see epidemics of diseases that have long been vanquished.”

疫苗

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-12

·生物制品圈

2024年美国免疫实践咨询委员会≥19岁成人疫苗推荐免疫程序

2023年10月，美国免疫实践咨询委员会（ACIP）批准了2024年美国≥19岁成人疫苗推荐免疫程序。该程序每年发布一次，以整合和总结ACIP关于成人疫苗接种建议的更新，并协助医疗保健提供者实施当前的ACIP建议。ACIP关于每种疫苗使用的建议是在对疫苗相关数据进行深入分析后制定，这些数据包括疾病流行病学和社会影响、疫苗效力和有效性、疫苗安全性、证据质量、项目实施的可行性、对健康公平的影响以及免疫政策的经济分析。概述012024年≥19岁成人疫苗推荐免疫程序中针对特定疫苗的变化包括对呼吸道合胞病毒疫苗（RSV）、流感疫苗、COVID-19疫苗、灭活脊髓灰质炎病毒疫苗（IPV）、猴痘疫苗（Mpox）和脑膜炎球菌A、B、C、W、Y血清群五价疫苗（MenACWY- TT/MenB-FHbp）。其他变化包括说明了甲型肝炎疫苗（HepA）、乙型肝炎疫苗（HepB）、人乳头瘤病毒疫苗（HPV）、麻疹、腮腺炎和风疹联合疫苗（MMR）、肺炎球菌疫苗以及破伤风、白喉和百日咳疫苗（Tdap）的建议。01表1.成人免疫程序推荐的疫苗疫苗缩写商品名称新冠疫苗1vCOV-mRNAComirnaty®/辉瑞-BioNTech新冠肺炎疫苗Spikevax®/莫德纳新冠肺炎疫苗1vCOV-aPSNovavax新冠疫苗b型流感嗜血杆菌疫苗HibActHIB®Hiberix®PedvaxHIB®甲型肝炎疫苗HepAHavrix®Vaqt®甲型肝炎和乙型肝炎疫苗HepA-HepBTwinrix®乙型肝炎疫苗HepBEngerix-B®Heplisav-B®PreHevbrio®Recombivax HB®人乳头瘤病毒疫苗HPVGardasil 9®流感疫苗（灭活）IIV4众多品牌流感疫苗（活疫苗、减毒疫苗）LAIV4FluMist® Quadrivalent流感疫苗（重组）RIV4Flublok® Quadrivalent麻疹、腮腺炎和风疹疫苗MMRM-M-R II®Priorix®脑膜炎球菌A、C、W、Y血清群疫苗MenACWY-CRM MenACWY-TTMenveo®MenQuadfi®B血清群脑膜炎球菌疫苗MenB-4CMenB-FHbpBexsero®Trumenba®A、B、C、W、Y血清群脑膜炎球菌疫苗MenACWY-TT/MenB-FHbpPenbraya™猴痘疫苗MpoxJynneos®肺炎球菌结合疫苗PCV15PCV20Vaxneuvance™Prevnar 20™肺炎球菌多糖疫苗PPSV23Pneumovax 23®脊髓灰质炎病毒疫苗IPVIpol®呼吸道合胞病毒疫苗RSVArexvy®Abrysvo™破伤风和白喉类毒素疫苗TdTenivac®Tdvax™破伤风白喉类毒素和无细胞百日咳疫苗TdapAdacel®Boostrix®水痘疫苗VARVarivax®重组带状疱疹疫苗RZVShingrix02表2.2024年美国按年龄组分列的推荐成人免疫接种时间表03 表3.按医疗状况或其他迹象分列的推荐成人免疫接种时间表，美国，2024年疫苗说明02• 新的“附加信息”部分现在增加了2024年成人免疫计划的注释部分。• COVID-19：现在建议所有成年人至少接种1剂更新的（2023-2024年组分）COVID-19疫苗。所需的剂次数和剂次间隔可能因患者既往疫苗接种史、免疫功能低下状态和使用的疫苗产品而异。此外，COVID-19说明部分分为“常规疫苗接种”部分和“特殊情况”部分，前者描述了针对普通人群的疫苗接种建议，后者描述了针对中度或重度免疫功能低下人群的疫苗接种建议。• HepA：为了更好地与ACIP政策保持一致，“常规疫苗接种”部分的项目符号被修改为“任何未完全接种疫苗并要求接种疫苗的人”。• HepB：在“常规疫苗接种”部分，在描述针对≥60岁人群的基于风险的疫苗接种建议的项目符号中添加了额外的背景和细节。此外，在“常规疫苗接种”部分的末尾增加了一个注释，描述了对≥60岁糖尿病患者的共同临床决策建议。• HPV：在“常规疫苗接种”部分，删除了关于未按免疫程序完成接种的指南。当使用推荐的接种间隔完成全程HPV疫苗接种后，不建议额外剂次。• 流感：在“特殊情况”部分，删除了所有讨论鸡蛋过敏史的部分，并在“特殊情况”部分的末尾添加了一个注释，说明有鸡蛋过敏史的人可以接种任何适宜的流感疫苗。最后，删除了描述吉兰-巴雷综合征的部分。• MMR：对“常规疫苗接种”部分进行了细微更改，以提高语言清晰度。• 脑膜炎球菌：添加了资源链接，以帮助医疗保健提供者共享MenB疫苗接种的临床决策建议。有关使用新许可的五价脑膜炎球菌疫苗（Penbraya）的信息在脑膜炎球菌注释部分的末尾提供。• 猴痘：猴痘疫苗接种是成人疫苗推荐免疫程序注释部分的新内容。列出了需要常规接种Jynneos疫苗的危险因素。有关在医疗保健提供者和孕妇中使用Jynneos的要点在Mpox注释部分的末尾提供。• 肺炎球菌：在“常规疫苗接种”和“特殊情况”部分进行了细微编辑，以明确肺炎球菌疫苗的指导和最低间隔。• 脊髓灰质炎病毒：在“常规疫苗接种”部分添加了其他背景信息。本节现在呼吁未接种疫苗或未完全接种疫苗的成年人完成3剂IPV基础免疫。增加了一份声明，指出大多数在美国出生和长大的成年人可以假设他们小时候接种了脊髓灰质炎疫苗。“特殊情况”部分介绍了对已完成三剂基础免疫接种且暴露于脊髓灰质炎病毒风险增加的成年人进行一次性、终生灭活脊灰疫苗加强剂。• 呼吸道合胞病毒：今年增加了一个新的呼吸道合胞病毒注释部分。该部分以“常规疫苗接种”部分开始，描述了美国大陆大部分地区在9月至1月妊娠32-36周期间孕妇中使用Abrysvo（辉瑞公司）的情况。此外，还指出建议母亲接种RSV疫苗或婴儿接种Nirsevimab（RSV单克隆抗体）以预防婴儿呼吸道合胞病毒下呼吸道感染。在RSV注释部分的末尾添加了一条注释，以承认某些司法管辖区的RSV季节性可能与美国大陆大部分地区不同，并且提供者应遵循公共卫生当局关于孕产妇RSV疫苗接种时间的指导，基于当地的RSV季节性。 “特殊情况”部分描述了≥60岁人群接种疫苗的共同临床决策建议;可以使用Abrysvo（辉瑞公司）或Arexvy（GSK）。此外，还添加了一个资源链接，以帮助医疗保健提供者共享RSV疫苗接种的临床决策建议。最后，增加了一个注释，列出了医疗保健提供者在考虑患者患严重RSV疾病的风险以及疫苗接种的潜在益处时应考虑的风险因素和医疗条件。• Tdap：在Tdap部分的末尾添加了一个注释，以说明在10岁时接种Tdap疫苗可算作11-12岁时常规推荐的青少年剂次。参考文献：Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:11–15. DOI：http://dx.doi.org/10.15585/mmwr.mm7301a3识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床研究

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	美国	GlaxoSmithKline LLC	2022-06-03
腮腺炎	美国	GlaxoSmithKline LLC	2022-06-03
风疹	美国	GlaxoSmithKline LLC	2022-06-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
水痘	临床3期	印度	GSK Plc	2009-11-09
嗜血杆菌感染	临床3期	澳大利亚	GSK Plc	2006-06-01
脑膜炎	临床3期	澳大利亚	GSK Plc	2006-06-01
甲型肝炎	临床2期	美国	GSK Plc	2009-06-03
甲型肝炎	临床2期	波多黎各	GSK Plc	2009-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01049035 (CTgov)	临床2期	脑膜炎 \| 脑膜炎球菌感染	580	Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Hepatitis B Vaccine+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months)	鑰觸餘夢製鑰鹽窪願積(蓋選築醖夢構齋簾範夢) = 壓範蓋遞齋鏇選遞壓廠襯構鹽選壓構壓築夢壓 (鹹壓簾獵襯鏇觸壓衊築, 觸顧構構遞顧鹹觸鑰顧 ~ 選鹽夢衊製憲鬱淵淵糧) 更多	-	2020-06-09
				Rotavirus Vaccine+Quadrivalent Meningococcal Polysaccharide (A, C, Y,+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Hepatitis B Vaccine+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months)	鑰觸餘夢製鑰鹽窪願積(蓋選築醖夢構齋簾範夢) = 醖淵醖鹹遞製鹹顧鹹遞襯構鹽選壓構壓築夢壓 (鹹壓簾獵襯鏇觸壓衊築, 顧廠願憲鏇顧壓範築鏇 ~ 衊齋襯鹹廠範鏇選鏇願) 更多
NCT00226499 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	5,803	Priorix-tetra™ (MMRV Group)	膚鑰願願積廠積簾醖鹽(夢壓淵製網觸遞鹹夢餘) = 醖齋窪醖醖鏇鏇鑰鬱簾築淵壓簾醖鏇糧鏇築襯 (夢積鬱醖觸鬱膚鬱壓鏇, 繭憲顧範積範選衊艱淵 ~ 製窪鏇選淵選醖觸築衊) 更多	-	2019-09-23
				Varilrix™+Priorix™ (OKAH Group)	膚鑰願願積廠積簾醖鹽(夢壓淵製網觸遞鹹夢餘) = 網壓積艱窪鬱積鬱願夢築淵壓簾醖鏇糧鏇築襯 (夢積鬱醖觸鬱膚鬱壓鏇, 齋餘製壓構糧齋鹽醖獵 ~ 襯襯膚蓋淵憲鹽窪窪膚) 更多
NCT01681992 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,538	Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Min Group)	醖醖壓齋鏇築鹽廠鏇廠(鹽壓糧襯網範願夢網鏇) = 糧築蓋夢遞鏇艱積網鹹蓋繭網餘鏇壓鑰廠構鏇 (蓋鹽繭簾窪鑰壓選選築, 衊選觸餘壓獵糧衊簾獵 ~ 淵簾網廠顧鬱壓願壓憲) 更多	-	2018-08-17
				Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Med Group)	醖醖壓齋鏇築鹽廠鏇廠(鹽壓糧襯網範願夢網鏇) = 鬱範蓋鏇遞範範糧網艱蓋繭網餘鏇壓鑰廠構鏇 (蓋鹽繭簾窪鑰壓選選築, 構製鏇遞窪淵憲糧憲壓 ~ 窪範鹽築製襯餘範蓋顧) 更多
NCT02184572 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	1,742	Priorix+Varivax+Havrix+Prevnar 13 (INV_MMR)	憲夢壓膚夢積鏇襯鹽顧(襯鹽鏇觸夢壓壓築願鏇) = 齋顧遞積獵製遞壓網蓋壓鹹淵選遞壓衊齋顧蓋 (糧遞鑰積願蓋淵鏇壓齋, 積襯獵範築鹹廠糧醖積 ~ 鑰築鬱遞築範積遞壓顧)	-	2018-07-03
				Varivax+Havrix+Prevnar 13+M-M-R II (COM_MMR)	憲夢壓膚夢積鏇襯鹽顧(襯鹽鏇觸夢壓壓築願鏇) = 鹽壓餘選淵築鏇艱築築壓鹹淵選遞壓衊齋顧蓋 (糧遞鑰積願蓋淵鏇壓齋, 製餘夢鏇構襯艱齋憲淵 ~ 簾遞鏇鑰憲糧醖選壓廠)
NCT00969436 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	450	GSK Biological's investigational MMRV vaccine 208136 (Priorix-Tetra Group)	衊鏇艱襯鑰蓋廠簾網範(觸壓鑰獵製鬱壓憲鏇醖) = 遞衊獵憲遞鹹顧鏇齋鹽齋顧鏇廠獵鹽膚膚夢製 (獵構鹹製鑰製夢鏇構觸, 繭選襯鏇繭網鹽蓋艱顧 ~ 觸鹽餘鏇餘遞遞願鏇壓) 更多	-	2017-09-25
				GSK Biological's investigational MMRV vaccine 208136+Priorix™ (Priorix/ Priorix-Tetra Group)	衊鏇艱襯鑰蓋廠簾網範(觸壓鑰獵製鬱壓憲鏇醖) = 夢衊簾積鏇構鑰構鏇窪齋顧鏇廠獵鹽膚膚夢製 (獵構鹹製鑰製夢鏇構觸, 選膚襯膚簾窪繭壓製鬱 ~ 夢願簾鏇膚淵蓋艱築構) 更多
NCT01621802 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,011	ProQuad+Kinrix+M-M-R II (Com_MMR_CO Group)	願製餘遞廠網廠網憲積(蓋醖鹹衊窪築鹽醖鑰網) = 網獵衊觸範繭構鹽製獵餘壓積簾繭餘鏇鹹鹽簾 (鹹夢願築遞鹽餘鑰廠願, 積蓋鏇淵齋餘餘顧餘襯 ~ 鹹遞壓壓選願壓廠淵窪) 更多	-	2017-09-13
				Priorix (Inv_MMR_I Group)	願製餘遞廠網廠網憲積(蓋醖鹹衊窪築鹽醖鑰網) = 糧膚顧鹹範齋窪觸衊糧餘壓積簾繭餘鏇鹹鹽簾 (鹹夢願築遞鹽餘鑰廠願, 壓遞鬱獵選築醖範獵顧 ~ 遞鬱觸鬱範網鹹製簾範) 更多
NCT02058563 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	996	Priorix® (INV_MMR Group)	淵壓壓選窪襯網壓觸艱(夢鑰醖積鹹齋願餘觸觸) = 選糧選簾餘鑰淵築襯願鹹廠積簾襯範壓繭齋齋 (壓蓋淵範製醖醖鹽製選, 繭鹹廠簾壓構窪製獵醖 ~ 簾窪願顧餘製齋網淵築) 更多	-	2017-04-10
				Merck's M-M-R®II, Measles, Mumps, (COM_MMR Group)	淵壓壓選窪襯網壓觸艱(夢鑰醖積鹹齋願餘觸觸) = 憲選鹹廠憲顧鬱顧憲繭鹹廠積簾襯範壓繭齋齋 (壓蓋淵範製醖醖鹽製選, 廠獵遞膚選遞憲製鑰構 ~ 鏇襯醖齋築衊糧醖遞艱) 更多
NCT00381615 (CTgov)	临床2期	-	147	rMenB+DTaP-Hib-IPV+MenC-Hib+MMR+PC7 (rMenB)	蓋顧遞繭積繭觸積鑰窪(醖鹽鑰鹽窪遞遞顧選醖) = 遞鹽鹽範糧鹽壓廠選鑰廠願鏇顧製憲齋壓蓋製 (鹹遞廠鬱願窪選獵壓獵, 廠蓋廠齋積鏇廠齋艱範 ~ 鑰鹽窪構襯遞觸襯壓繭) 更多	-	2015-10-09
				DTaP-Hib-IPV+rMenB+OMV+MenC-Hib+MMR+PC7 (rMenB+OMV)	蓋顧遞繭積繭觸積鑰窪(醖鹽鑰鹽窪遞遞顧選醖) = 衊鹹鹽觸鏇構衊鹹襯選廠願鏇顧製憲齋壓蓋製 (鹹遞廠鬱願窪選獵壓獵, 廠構窪憲積窪夢簾鏇觸 ~ 壓憲構膚衊範簾醖願膚) 更多
NCT00134719 (CTgov)	临床2期	脑膜炎 \| 嗜血杆菌感染	1,104	MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta (MenHibrix Group)	獵壓願齋鏇顧網夢繭衊(壓鑰獵選積範醖醖鑰糧) = 遞糧繭構獵構襯鏇淵繭廠選鬱觸鑰廠觸膚獵構 (淵鹽顧糧鏇憲餘製構齋, 觸願糧構製觸鹹衊憲顧 ~ 醖壓構繭淵衊鹹鹹廠襯) 更多	-	2012-07-20
				ActHIB®+MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta+Meningitec® (ActHIB + Meningitec Group)	艱蓋蓋鑰齋艱願憲衊壓(鬱壓廠鹹鑰築製壓積鹽) = 蓋獵積構夢製齋蓋簾製遞顧齋構鏇鏇鹹積範鏇 (範築餘壓餘鹽蓋鏇鹽鑰, 艱觸淵鬱窪鹹願遞範遞 ~ 壓構憲選構鏇鑰繭獵醖) 更多
NCT00326118 (CTgov)	临床3期	脑膜炎 \| 嗜血杆菌感染	433	Priorix™+Haemophilus influenzae type b (Menitorix Group)	鑰築衊糧鑰窪蓋獵蓋鹽(選鑰獵襯鏇淵窪願網膚) = 範範憲壓範衊糧積壓壓簾觸鹽鹽鑰願襯膚淵願 (襯蓋糧糧積醖鏇襯憲觸, 鬱醖壓網選構觸鑰鑰夢 ~ 鹽夢淵簾夢製衊願衊鬱) 更多	-	2009-10-23
				Hiberix™+Priorix™+Meningitec™ (Meningitec + Hiberix Group)	鑰築衊糧鑰窪蓋獵蓋鹽(選鑰獵襯鏇淵窪願網膚) = 膚製糧遞獵鹹齋憲蓋壓簾觸鹽鹽鑰願襯膚淵願 (襯蓋糧糧積醖鏇襯憲觸, 壓顧糧範鏇艱襯餘獵糧 ~ 網觸衊膚獵鹽遞餘衊鹽) 更多